Since the approval of recombinant tissue-type plasminogen activator (r-tPA) as a treatment for ischemic stroke by the FDA in 1996 and EMA in 2002, patients eligible for treatment have been selected based on time since symptom onset. Here, PLAT is linked to ischemic stroke.